Market Cap (In USD)
449.26 Million
Revenue (In USD)
-
Net Income (In USD)
-63.77 Million
Avg. Volume
403.05 Thousand
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 11.51-22.188
- PE
- -
- EPS
- -
- Beta Value
- 0.754
- ISIN
- US15102K1007
- CUSIP
- 15102K100
- CIK
- 1603454
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Brian F. Sullivan
- Employee Count
- -
- Website
- https://www.celcuity.com
- Ipo Date
- 2017-09-20
- Details
- Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.
More Stocks
-
IONM
-
VAIBHAVGBLVaibhav Global Limited
VAIBHAVGBL
-
5276
-
HLMAHalma plc
HLMA
-
PNCINFRAPNC Infratech Limited
PNCINFRA
-
WINMED
-
1FCFACC AG
1FC
-
BLFS